Gilead Sciences: ‘Far From Compelling’
October 20, 2016 at 11:10 AM EDT
Remember when Gilead Sciences ( GILD ) got a pop when Allergan ( AGN ) made a small bet on NASH ? Well, Gilead released some results from a Phase 2 trial of its NASH treatment, and they were "far from compelling," says Piper Jaffray analyst Joshua Schimmer and team. They explain why:
